

Muscular Dystrophy Duchenne Muscular Dystrophy (DMD)

## Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

**Trial Status**  
Terminated

**Trial Runs In**  
2 Countries

**Trial Identifier**  
NCT02515669 WN40226  
CN001-006

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

The purpose of this study is to determine the safety and tolerability of RO7239361 in boys with Duchenne Muscular Dystrophy with any genetic mutation.

**Hoffmann-La Roche**  
Sponsor

**Phase 1/Phase 2**  
Phase

---

**NCT02515669 WN40226 CN001-006**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
Male

**Age**  
≥5 Years & ≤ 10 Years

**Healthy Volunteers**  
No

---